EMSY
EMSY (BRCA2-interacting transcriptional repressor EMSY) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.
Overview
Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin. Its interaction with BRCA2 suggests that it may play a central role in the DNA repair function of BRCA2. Mediates ligand-dependent transcriptional activation by nuclear hormone receptors.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Bevacizumab, Paclitaxel, Carboplatin and Talazoparib.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · EMSY (BRCA2-interacting transcriptional repressor EMSY) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.
- 1 · What it is
EMSY (BRCA2-interacting transcriptional repressor EMSY) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.
- 2 · What goes wrong in cancer
Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin.
- 3 · How drugs use it
No product in this corpus aims at EMSY yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:18071 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q7Z589 (protein name, function text, keywords and locations (REST API)); CIViC gene EMSY (2 evidence items, 0 assertions, 2 variants; diseases: Ovarian Serous Carcinoma, Acral Lentiginous Melanoma (GraphQL API, CC0))
Biology
Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin. Its interaction with BRCA2 suggests that it may play a central role in the DNA repair function of BRCA2. Mediates ligand-dependent transcriptional activation by nuclear hormone receptors. Location: Nucleus (UniProt). Locus 11q13.5 (HGNC).
- Ovarian cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; CIViC holds 2 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Acral Lentiginous Melanoma.
Latest papers
topQuery for this target: (TITLE:"EMSY" OR ABSTRACT:"EMSY" OR TITLE:"EMSY transcriptional repressor, BRCA2 interacting" OR ABSTRACT:"EMSY transcriptional repressor, BRCA2 interacting" OR TITLE:"BRCA2-interacting transcriptional repressor EMSY" OR ABSTRACT:"BRCA2-interacting transcriptional repressor EMSY" OR TITLE:"C11orf30" OR ABSTRACT:"C11orf30") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EMSY, not a curated reading list.